What is Neuropace Inc (NPCE) stock price today?

Neuropace Inc (NPCE) currently trades at $16.86 per share. The stock has a market capitalization of $585.64M and a P/E ratio of —x.

Is NPCE stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Neuropace Inc has a Smart Value Score of 29/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Neuropace Inc's revenue and earnings?

Neuropace Inc has trailing twelve-month (TTM) revenue of $99.99M with profit margins of -21.50%. Earnings per share (EPS) is $-0.66.

Is NPCE stock overvalued or undervalued?

Based on our DCF model, Neuropace Inc's intrinsic value is $15.59, representing a margin of safety of 6.61%. The stock currently trades at a P/E of —x.

NPCE

Neuropace Inc

NASDAQ: NPCE · HEALTHCARE · MEDICAL DEVICES

$16.86

+1.93% today

Updated 2026-04-30

Market cap

$585.64M

P/E ratio

—

P/S ratio

5.86x

EPS (TTM)

$-0.66

Dividend yield

—

52W range

$8 – $19

Volume

0.2M

Market cap

$585.64M

P/E ratio

—

P/S ratio

5.86x

EPS (TTM)

$-0.66

Dividend yield

—

52W range

$8 – $19

Volume

0.2M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

7.3

Growth

B+

5.0

Quality

C+

2.0

Profitability

5.3

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$19.88

+17.91%

12-Month target

—

Intrinsic (DCF)

$15.59

Margin of safety

+6.61%

1 Strong Buy7 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Free cash flow $409000.00 — positive

+ Revenue growth 23.90% QoQ

Risks

- Thin margins at -21.50%

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$45.52M	$65.42M	$79.91M	$99.99M	$99.99M
Net income	$-47.08M	$-32.96M	$-27.14M	$-21.46M	$-2.73M
EPS	—	—	—	—	$-0.66
Free cash flow	$-37.47M	$-19.87M	$-18.25M	$-11.34M	$409000.00
Profit margin	-103.43%	-50.38%	-33.97%	-21.47%	-21.50%

Recent insider activity

Date	Insider	Type	Shares	Price
2026-03-24	MORRELL, MARTHA	Sale	1,341	$13.27
2026-03-20	LACOB, JOSEPH	Buy	865	$13.00
2026-03-20	KUMAR, RAKHI	Buy	1,153	$13.00

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
NPCE	$585.64M	29	7.3	2.0	5.3	5.0	+6.61%	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Neuropace Inc trades at $16.86. Our Smart Value Score of 29/100 indicates the stock is weak. TTM revenue stands at $99.99M. with profit margins at -21.50%. Our DCF model estimates intrinsic value at $15.59.

Frequently asked questions

What is Neuropace Inc's stock price?

Neuropace Inc (NPCE) trades at $16.86.

Is Neuropace Inc overvalued?

Smart Value Score 29/100 (Grade F, Strong Sell). DCF value $15.59.

What is the price target of Neuropace Inc (NPCE)?

The analyst target price is $19.88, representing +17.9% upside from the current price of $16.86.

What is the intrinsic value of Neuropace Inc (NPCE)?

Based on our DCF model, intrinsic value is $15.59, a +6.6% margin of safety versus $16.86.

What is Neuropace Inc's revenue?

TTM revenue is $99.99M.

Company info

SectorHEALTHCARE

IndustryMEDICAL DEVICES

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio5.86x

ROE-158.70%

Beta1.88

50D MA$14.57

200D MA$12.91

Shares out0.03B

Float0.02B

Short ratio—

Avg volume0.2M

Performance

1 week+5.38%

1 month+29.41%

3 months+8.15%

YTD+11.72%

1 year—

3 years—

5 years—

Compare

NPCE vs LLY →NPCE vs JNJ →NPCE vs ABBV →Stock screener →